Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30

$1.18−0.15 (-11.28%)

Close on Nov 13, 2026Market cap $118.40MP/E –Yield –

Cellectis EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cellectis has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLLS.

Revenue growth75.8% · median 7.4%

Operating margin-45.3% · median -151.7%

Net margin-92.7% · median -145.0%

Advertisement
300 × 250

See a number that looks wrong?